drugset / Trial / NCT00855205

Rituximab for Pulmonary Sarcoidosis

NCT00855205 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Sarcoidosis is a inflammatory disease affecting many parts of the body, especially the lungs. While most patients do well, there is a group of patients who require continuous doses of prednisone or other drugs. The current study will determine the role of Rituximab as new agent for patients with refractory disease.

Timeline

Start
2009-07
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 1000 mg Intravenous

Indications